These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8457224)

  • 1. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate.
    Manicourt DH; Triki R; Fukuda K; Devogelaer JP; Nagant de Deuxchaisnes C; Thonar EJ
    Arthritis Rheum; 1993 Apr; 36(4):490-9. PubMed ID: 8457224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest.
    Manicourt DH; Poilvache P; Nzeusseu A; van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
    Arthritis Rheum; 1999 Sep; 42(9):1861-9. PubMed ID: 10513800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.
    Manicourt DH; Fujimoto N; Obata K; Thonar EJ
    Arthritis Rheum; 1995 Aug; 38(8):1031-9. PubMed ID: 7639798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate.
    Poole AR; Witter J; Roberts N; Piccolo F; Brandt R; Paquin J; Baron M
    Arthritis Rheum; 1990 Jun; 33(6):790-9. PubMed ID: 2141981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
    Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
    Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate.
    Chubinskaya S; Frank BS; Michalska M; Kumar B; Merrihew CA; Thonar EJ; Lenz ME; Otten L; Rueger DC; Block JA
    Arthritis Res Ther; 2006; 8(3):R73. PubMed ID: 16646979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis.
    Straub RH; Paimela L; Peltomaa R; Schölmerich J; Leirisalo-Repo M
    Arthritis Rheum; 2002 Mar; 46(3):654-62. PubMed ID: 11920401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokine and periodontal profiles in relation to disease activity of rheumatoid arthritis in Japanese adults.
    Kobayashi T; Murasawa A; Komatsu Y; Yokoyama T; Ishida K; Abe A; Yamamoto K; Yoshie H
    J Periodontol; 2010 May; 81(5):650-7. PubMed ID: 20429644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis.
    He Y; Liu C; Zeng Z; Ye W; Lin J; Ou Q
    Clin Rheumatol; 2018 Jan; 37(1):161-167. PubMed ID: 29101675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
    Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
    J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis.
    Okamoto H; Yamamura M; Morita Y; Harada S; Makino H; Ota Z
    Arthritis Rheum; 1997 Jun; 40(6):1096-105. PubMed ID: 9182920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity.
    Emlen W; Niebur J; Flanders G; Rutledge J
    J Rheumatol; 1996 Jun; 23(6):974-8. PubMed ID: 8782125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis.
    Szeremeta A; Jura-Półtorak A; Koźma EM; Głowacki A; Kucharz EJ; Kopeć-Mędrek M; Olczyk K
    Arthritis Res Ther; 2018 Sep; 20(1):211. PubMed ID: 30227885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs.
    Straub RH; Müller-Ladner U; Lichtinger T; Schölmerich J; Menninger H; Lang B
    Br J Rheumatol; 1997 Dec; 36(12):1298-303. PubMed ID: 9448591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis.
    Hein GE; Köhler M; Oelzner P; Stein G; Franke S
    Rheumatol Int; 2005 Dec; 26(2):137-41. PubMed ID: 15580352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis.
    Goldberg RL; Huff JP; Lenz ME; Glickman P; Katz R; Thonar EJ
    Arthritis Rheum; 1991 Jul; 34(7):799-807. PubMed ID: 2059228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis.
    Manicourt DH; Fujimoto N; Obata K; Thonar EJ
    Arthritis Rheum; 1994 Dec; 37(12):1774-83. PubMed ID: 7986224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.